In this issue of Kidney International, The Dialysis Outcomes and Practice Patterns Study reports that hemodialysis patients with monthly intravenous iron supplementation of 300-399 mg or ≥400 mg had a 13 or 18% higher risk of dying, respectively, compared with those receiving 100-199 mg per month, with no obvious differences in cause-specific mortalities. This study supports that randomized controlled trials are urgently needed to identify optimized iron supplementation strategies for anemic dialysis patients.
CITATION STYLE
Weiss, G., & Kronenberg, F. (2015, January 3). Intravenous iron administration: New observations and time for The next steps. Kidney International. Nature Publishing Group. https://doi.org/10.1038/ki.2014.324
Mendeley helps you to discover research relevant for your work.